Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions
Dry Eye Syndromes
Interventions
DRUG

RP101

17β-oestradiol-3-phosphate ophthalmic sterile solution

Trial Locations (8)

1036

Óbudai Egészség Centrum, Budapest

1090

Medical University of Vienna - Department of Clinical Pharmacology, Vienna

3526

MacroKlinika, Miskolc

4281

Swan Med Hungary Kft., Létavértes

8000

Mentaház Magánorvosi Központ, Székesfehérvár

17475

Universitätsmedizin Greifswald, Klinik und Poliklinik für Augenheilkunde, Greifswald

55131

Universitätsmedizin Mainz Augenklinik und Poliklinik Klinisches, Mainz

81675

Klinikum rechts der Isar der Technischen Universität München, Anstalt des öffentlichen Rechts Klinik und Poliklinik für Augenheilkunde, München

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cross Research S.A.

INDUSTRY

lead

Redwood Pharma AB

INDUSTRY

NCT03821415 - Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome | Biotech Hunter | Biotech Hunter